• Login
    • Login
    Advanced Search
    View Item 
    •   UoN Digital Repository Home
    • Journal Articles
    • Faculty of Health Sciences (FHS)
    • View Item
    •   UoN Digital Repository Home
    • Journal Articles
    • Faculty of Health Sciences (FHS)
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Experience with rituximab in patients with rheumatoid arthritis in Nairobi, Kenya

    Thumbnail
    Date
    2015
    Author
    Oyoo, GO
    Otieno, FO
    Mbuthia, B
    Omondi, EA
    Genga, EK
    Type
    Article; en
    Language
    en
    Metadata
    Show full item record

    Abstract
    Background: Rheumatoid Arthritis (RA) is a disease associated with significant morbidity and mortality. Newer therapies include B-cell targeted therapies such as rituximab. Objectives: To study the outcome in RA patients receiving rituximab following resistance to Disease Modifying Anti- Rheumatic Agents (DMARDS) and to determine the change in disease activity and functional status. Methods: A longitudinal prospective study was carried out on RA patients in Nairobi, Kenya. Patients resistant to DMARDS and on rituximab therapy were identified. Their disease activity was assessed using the Simplified Disease Activity Index (SDAI) and the functional status determined using Health Assessment Questionnaire-Disability Index (HAQ DI). The scores were recorded at the beginning of the study then at 3 and 6 months after the initiation of rituximab therapy. Results: Forty-one patients (36 females and 5 males) receiving rituximab were recruited in this study. At baseline, 18 had moderate and 23 with high disease activity. After 6 months, 7% were in remission, 11% with low, 17 moderate and 6 with high disease activity. There was significant improvement in the SDAI scores witnessed in 13(31.7%) patients in first 3 months and in 22(53.7%) patients after 6 months. There was a significant improvement in the functional and disability score in 95% of the patients after 6 months. There was no significant correlation between the SDAI and the different variables as age, disease duration, type of DMARD and steroids used. Conclusion: Rituximab use resulted in improvement of disease activity, functional status and disability index in patients with RA in Nairobi
    URI
    http://www.ajol.info/index.php/ajr/article/view/117381
    http://hdl.handle.net/11295/84320
    Citation
    African Journal of Rheumatology Vol 3, No 1 (2015)
    Subject
    Rituximab
    Rheumatoid arthritis
    SDAI
    HAQI
    Nairobi
    Kenya
    Collections
    • Faculty of Health Sciences (FHS) [10214]

    Copyright © 2022 
    University of Nairobi Library
    Contact Us | Send Feedback

     

     

    Useful Links
    UON HomeLibrary HomeKLISC

    Browse

    All of UoN Digital RepositoryCommunities & CollectionsBy Issue DateAuthorsTitlesSubjectsThis CollectionBy Issue DateAuthorsTitlesSubjects

    My Account

    LoginRegister

    Copyright © 2022 
    University of Nairobi Library
    Contact Us | Send Feedback